VEGFR-3 expression profiling by histology and biomarkers strategy to classify patient population for the selective VEGFR-3 inhibitor EVT801

Carlos Gomez-Roca, Philippe Cassier, Philippe Rochaix, Jean-Pierre Delord, Uze Davenne, Pierre-Benoît Ancey, Oona Delpech, Vincent Piras, Michael Paillas, John Friend, Michael Fitzgerald & Pierre Fons

*Corresponding author: pierre.fons@evotec.com

1) Oncopole IUTC, Toulouse, France, 2) Centre Léon Bérard, Lyon, France, 3) Evotec, Toulouse, France, 4) Kazia Therapeutics, Sydney, Australia

**Correlation between VEGFR3 expression and CAIX by histology**

Correlation of VEGFR3 mRNA expression with CAIX (histology)

**Conclusion and next steps**

- In HGS-OC patients enrolled, VEGFR3 expression tends to be positively correlated with hypoxia and PDs mAb resistance signature & negatively correlated with CDP™ T-cell infiltration.
- The correlations in HGS-OC patients are highly encouraging and informational while aligning with the EVT801 mechanism of action.
- Patients with hypoxic HGS-OC tumour poorly infiltrated with CDP™ T-cells and with high VEGFR3 expression could benefit from EVT801 treatment.